CHINA SXT PHARMACEUTICALS IN (SXTC)
VGG2161P1403 - Common Stock
Overall SXTC gets a fundamental rating of 1 out of 10. We evaluated SXTC against 193 industry peers in the Pharmaceuticals industry. SXTC may be in some trouble as it scores bad on both profitability and health. SXTC does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year SXTC has reported negative net income.
In the past year SXTC has reported a negative cash flow from operations.
In the past 5 years SXTC always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: SXTC reported negative operating cash flow in multiple years.
1.2 Ratios
SXTC has a Return On Assets of -13.40%. This is in the better half of the industry: SXTC outperforms 68.06% of its industry peers.
SXTC has a Return On Equity of -22.24%. This is in the better half of the industry: SXTC outperforms 70.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.4% | ||
| ROE | -22.24% | ||
| ROIC | N/A |
ROA(3y)-16.86%
ROA(5y)-21.19%
ROE(3y)-32.52%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SXTC has a Gross Margin of 28.73%. This is comparable to the rest of the industry: SXTC outperforms 53.93% of its industry peers.
SXTC's Gross Margin has declined in the last couple of years.
SXTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.51%
GM growth 5Y-15.27%
2. Health
2.1 Basic Checks
SXTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SXTC has been increased compared to 1 year ago.
Compared to 5 years ago, SXTC has more shares outstanding
SXTC has a better debt/assets ratio than last year.
2.2 Solvency
SXTC has an Altman-Z score of -1.42. This is a bad value and indicates that SXTC is not financially healthy and even has some risk of bankruptcy.
SXTC has a Altman-Z score (-1.42) which is comparable to the rest of the industry.
SXTC has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
SXTC has a Debt to Equity ratio (0.04) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.42 |
ROIC/WACCN/A
WACC4.6%
2.3 Liquidity
A Current Ratio of 1.60 indicates that SXTC should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.60, SXTC is doing worse than 68.59% of the companies in the same industry.
A Quick Ratio of 1.51 indicates that SXTC should not have too much problems paying its short term obligations.
SXTC has a Quick ratio of 1.51. This is in the lower half of the industry: SXTC underperforms 63.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 44.52% over the past year.
Looking at the last year, SXTC shows a decrease in Revenue. The Revenue has decreased by -2.11% in the last year.
SXTC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.75% yearly.
EPS 1Y (TTM)44.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.83%
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y-26.11%
Revenue growth 5Y-22.75%
Sales Q2Q%30.12%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
SXTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
SXTC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHINA SXT PHARMACEUTICALS IN
NASDAQ:SXTC (12/18/2024, 6:20:10 PM)
After market: 0.3475 +0.01 (+3.73%)0.335
-0.01 (-1.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.17M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.4% | ||
| ROE | -22.24% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)44.52%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y-26.11%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y